Harbour BioMed Enters Multi-Year HCAb Technology Licensing Agreement with a Top-Ten Global Pharma for Next Generation Human Antibody Discovery - Yahoo Finance
Harbour BioMed Enters Multi-Year HCAb Technology Licensing Agreement with a Top-Ten Global Pharma for Next Generation Human Antibody Discovery Yahoo Finance
Technology produces novel heavy chain-only antibodies for bi-specific, single domain antibodies or CAR-Ts.
Comments
Post a Comment